Scientist in the Lab


epiSCI is developing proprietary in vitro tumor models for 200 carcinoma indications, including rare and underserved cancers, one carcinoma at a time.

Leveraging our biomarker discovery, and our accumulated knowledge database, our pipeline includes targeted nanodelivery of oncology drugs. 

Our first drugs in preclinical development TSK-001, and TSK-002 for oral carcinoma and prostate cancer respectively are activatable cell penetrating peptides tagged with a warhead and directed against the cancer stem cells that have undergone epithelial to mesenchymal transition.